KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Assets (2016 - 2025)

Historic Assets for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $7.6 billion.

  • Biomarin Pharmaceutical's Assets rose 1114.66% to $7.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 billion, marking a year-over-year increase of 1114.66%. This contributed to the annual value of $7.0 billion for FY2024, which is 215.35% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Assets stood at $7.6 billion, which was up 1114.66% from $7.5 billion recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Assets high stood at $7.6 billion for Q3 2025, and its period low was $5.8 billion during Q1 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median Assets value was $6.6 billion (recorded in 2023), while the average stood at $6.6 billion.
  • Data for Biomarin Pharmaceutical's Assets shows a peak YoY increase of 2291.44% (in 2021) and a maximum YoY decrease of 293.3% (in 2021) over the last 5 years.
  • Over the past 5 years, Biomarin Pharmaceutical's Assets (Quarter) stood at $6.0 billion in 2021, then rose by 6.17% to $6.4 billion in 2022, then increased by 7.32% to $6.8 billion in 2023, then increased by 2.15% to $7.0 billion in 2024, then rose by 8.96% to $7.6 billion in 2025.
  • Its last three reported values are $7.6 billion in Q3 2025, $7.5 billion for Q2 2025, and $7.1 billion during Q1 2025.